UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome
Status:
Terminated
Trial end date:
2017-12-05
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter, double-blind, placebo-controlled, 12-week proof-of-concept
study to assess the efficacy, safety, and tolerability of UCB5857 in subjects with primary
Sjögren's Syndrome (pSS).
The primary objective of this study is to evaluate the efficacy on overall disease activity
and safety of UCB5857 added to current treatment relative to placebo in subjects with pSS.